Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K, registration statements such as Form S‑1 and S‑1/A, proxy statements on Schedule 14A, and notifications of late filing on Form 12b‑25.
Through its filings, AIM ImmunoTech describes its business as an immuno-pharma company focused on research and development of therapeutics for cancers, viral diseases, and immune-deficiency disorders, with flagship products Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa. Registration statements and prospectuses detail capital-raising transactions, including offerings of common stock, pre‑funded warrants, Class E and Class F warrants, and rights offerings involving Series G Convertible Preferred Stock and warrants. These documents outline terms such as subscription rights, exercise prices, and use of proceeds.
Current reports on Form 8‑K capture material events, such as entry into a Note Purchase Agreement for an unsecured promissory note with an institutional investor, the closing of public offerings, the filing of corporate charter documents, and the release of corporate presentations. Filings also describe exchange listing matters, including temporary suspension of trading on the NYSE American, trading on the OTC Pink under a different symbol, and subsequent reinstatement on the NYSE American under the AIM symbol.
Investors can review notifications of late filing, such as Form 12b‑25, which explain delays in filing periodic reports and provide preliminary estimates of changes in revenues and net loss. Definitive proxy statements (DEF 14A) provide information on director elections, advisory votes on executive compensation, auditor ratification, and the company’s status as a smaller reporting company.
On Stock Titan, AIM ImmunoTech’s filings are updated as new documents are released on EDGAR. AI-powered summaries help explain the key points of lengthy filings, including risk factor discussions, financing structures, and governance proposals, so that readers can more quickly understand what each 10‑K, 10‑Q, 8‑K, or registration statement means for the company.
ImmunoTech Inc. director David I. Chemerow reported an indirect acquisition of common stock through The David I Chemerow 1992 Trust. On 02/05/2026, the trust acquired 2,800 shares of ImmunoTech common stock at a price of $1.23 per share.
Following this transaction, the trust beneficially owned a total of 3,441 ImmunoTech common shares, all reported as indirectly held on behalf of Chemerow.
ImmunoTech Inc. filed a current report describing new investor and clinical update materials. The company furnished a February 2026 corporate presentation, a DURIPANC year-end interim clinical progress update, and a February 5, 2026 press release as exhibits, noting these are furnished rather than filed for liability purposes.
The update relates to an ongoing Phase I/II open-label study combining durvalumab (Imfinzi) and rintatolimod (Ampligen) in pancreatic cancer patients with stable disease after FOLFIRINOX therapy. ImmunoTech emphasizes that Ampligen is still under evaluation across several diseases and that significant additional testing and human trials are required, with no assurance of successful or favorable outcomes.
ImmunoTech Inc. is launching a rights offering registering subscription rights to purchase up to 12,000 Units, each with one Series G Convertible Preferred share, plus securities convertible into up to 9,996,000 common shares and exercisable for up to 19,992,000 additional common shares.
Each Unit is offered at a $1,000 subscription price, with one non-transferable right per common share (including shares underlying participating options and warrants) held as of February 10, 2026, and an over-subscription privilege. The offer is best-efforts, with no minimum proceeds and an expected net raise of about $10.65 million if fully subscribed.
The company plans to use proceeds for general corporate purposes, clinical and manufacturing costs for prospective Phase 2/3 pancreatic cancer trials, and repayment of certain debt. The offering also supports efforts to regain NYSE American equity compliance while advancing Ampligen-based oncology, antiviral, ME/CFS and post-COVID programs.
ImmunoTech Inc. is conducting a rights offering of 12,000 Units at $1,000 per Unit, each Unit consisting of one share of Series G Convertible Preferred Stock and 1,492 warrants. The preferred shares are convertible into up to 8,952,000 shares of common stock, and the warrants are exercisable for up to 17,904,000 additional common shares at $1.34 per share for five years.
Existing common stockholders and holders of specified options and warrants as of 5:00 p.m. Eastern on February 4, 2026 receive one non-transferable subscription right per share, with a basic right to buy one Unit and an over-subscription privilege, subject to proration and a 19.99% ownership cap. The rights expire at 5:00 p.m. Eastern on February 23, 2026, and the offering is on a best-efforts basis with no minimum.
Assuming full subscription, ImmunoTech expects net proceeds of about $10.65 million, excluding any warrant exercises, and could receive an additional $23.99 million if all warrants are later exercised for cash. The company plans to use proceeds for general corporate purposes, including clinical and manufacturing costs for pancreatic cancer trials, and to repay certain existing debt, while highlighting significant dilution, liquidity and NYSE American listing risks.
AIM ImmunoTech Inc. filed a current report describing that it has furnished to warrant holders two notices dated January 20, 2026, detailing changes and modifications to its Class E and Class F Common Stock Purchase Warrants. These notices, included as Exhibits 99.1 and 99.2, outline revised terms for those existing warrants but are provided for information purposes under Regulation FD and are not deemed filed under securities laws. The company also reiterates standard forward-looking statement cautions and emphasizes that further clinical testing is required to determine the effectiveness of its product candidate Ampligen® across various conditions.
AIM ImmunoTech Inc. furnished its January 2026 Corporate Presentation as an exhibit to this report. The presentation is provided under Regulation FD to share updated corporate information with the market and is designated as “furnished,” meaning it is not treated as filed for certain liability purposes under federal securities laws.
The company reiterates that the presentation may contain forward-looking statements about its drug candidate Ampligen®, including current and anticipated future activities in viral diseases, cancers, and immune-deficiency disorders. AIM emphasizes that significant additional testing and human clinical trials are required, results from animal studies may not predict human outcomes, and there is no assurance that ongoing or planned clinical trials will be successful, yield favorable data, or proceed as expected. The company directs readers to the risk factors in its latest annual and quarterly reports for a fuller discussion of risks.
AIM ImmunoTech Inc. held its 2025 annual meeting of stockholders on December 16, 2025. A quorum was present, with 1,144,383 of 2,764,188 common shares represented in person or by proxy.
Stockholders voted on four proposals. All director nominees were elected, with individual support ranging from 243,183 to 280,350 votes in favor. Stockholders also strongly supported retaining BDO USA, P.C. as independent registered public accounting firm for 2025, with 1,104,780 votes for and 29,754 against.
The non-binding advisory vote on executive compensation saw 193,668 votes for, 115,337 against, 2,505 abstentions and 833,173 broker non-votes. Although a majority of votes cast supported the pay package, it did not receive the required majority in voting power represented and entitled to vote, and therefore was not approved. In a separate advisory vote on frequency of say-on-pay, 284,856 votes favored annual votes, and the board decided to hold this vote every year.
AIM ImmunoTech Inc. is launching a rights offering registering up to 12,000 Units at a subscription price of $1,000 per Unit, targeting gross proceeds of $12 million. Each Unit includes one share of Series G Convertible Preferred Stock and warrants to purchase common stock, all available only to existing common shareholders and certain warrant and option holders as of a 2025 record date.
Holders receive one non-transferable subscription right for each share (including shares underlying specified Participating Securities), with a basic right to buy one Unit and an over‑subscription privilege for any Units not initially purchased, subject to strict proration and ownership caps. AIM estimates net proceeds of about $10.9 million if the offering is fully subscribed, to be used for general corporate purposes and partial repayment of existing debt.
The preferred shares are convertible into common stock and the warrants are exercisable for common shares, creating potential dilution for investors who do not participate. AIM highlights that it is currently below the NYSE American $6 million stockholders’ equity requirement, with a stockholders’ deficit of approximately negative $6.1 million as of September 30, 2025, and is using this capital raise as part of its plan to regain compliance by June 11, 2026.
AIM ImmunoTech Inc. entered into a new financing agreement by issuing an unsecured promissory note with an original principal amount of $3,301,250 to Streeterville Capital, LLC in a private placement. After a $781,250 original issue discount and $20,000 of transaction costs, the company received cash proceeds of $2,500,000. The note bears 10% annual interest, compounded daily, and matures 24 months after issuance.
Each time the company raises money in any fundraising or financing transaction, it must prepay an amount equal to the lesser of 12.5% of the funds raised or the outstanding balance on the note. If an event of default occurs, the interest rate increases to up to 22%, subject to legal limits. Starting six months after funding, the investor may require monthly cash redemptions of up to $250,000, with any unused monthly amounts carrying forward, and the company must pay within three business days of notice.
AIM ImmunoTech Inc. reported another loss-making quarter while facing serious financial pressures and exchange-listing risks. For the three months ended September 30, 2025, revenue from clinical treatment programs was only $26,000, against operating expenses of $2.5 million, leading to an operating loss of $2.4 million and a net loss of $3.3 million. For the first nine months of 2025, the company recorded a net loss of $9.8 million, compared with $11.4 million a year earlier. Cash and cash equivalents were $2.3 million, while total assets were $5.5 million and total liabilities $11.6 million, resulting in a stockholders’ deficit of $6.1 million. A new warrant liability of $7.3 million was recorded after an August 2025 equity and warrant financing. Management states that recurring losses, a working capital deficit and sub-minimum equity raise substantial doubt about the company’s ability to continue as a going concern. AIM executed a 1-for-100 reverse stock split in June 2025 to address low trading prices, and its stock was reinstated on NYSE American, but it must lift stockholders’ equity to at least $6.0 million by June 11, 2026 to remain in compliance.